120 related articles for article (PubMed ID: 20395337)
1. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
2.
Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
[TBL] [Abstract][Full Text] [Related]
3. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
[No Abstract] [Full Text] [Related]
4. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Yang H; Jager MJ; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Theranostic Efficacy of
Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Hsp90
Magwenyane AM; Mhlongo NN; Lawal MM; Amoako DG; Somboro AM; Sosibo SC; Shunmugam L; Khan RB; Kumalo HM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32295059
[TBL] [Abstract][Full Text] [Related]
8. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.
Sinha S; Pal K; Elkhanany A; Dutta S; Cao Y; Mondal G; Iyer S; Somasundaram V; Couch FJ; Shridhar V; Bhattacharya R; Mukhopadhyay D; Srinivas P
Int J Cancer; 2013 Mar; 132(5):1201-12. PubMed ID: 22806981
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?-A systematic review.
Magyar CTJ; Vashist YK; Stroka D; Kim-Fuchs C; Berger MD; Banz VM
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8039-8050. PubMed ID: 36966394
[TBL] [Abstract][Full Text] [Related]
10. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes.
Gillan V; O'Neill K; Maitland K; Sverdrup FM; Devaney E
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2699. PubMed ID: 24551261
[TBL] [Abstract][Full Text] [Related]
11. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic drugs in ovarian cancer.
Kumaran GC; Jayson GC; Clamp AR
Br J Cancer; 2009 Jan; 100(1):1-7. PubMed ID: 19002176
[TBL] [Abstract][Full Text] [Related]
13. 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth.
Wu C; Wang X; Tomko N; Zhu J; Wang WR; Zhu J; Wangf B; Wang Y; Salomon RG
Anticancer Agents Med Chem; 2017; 17(6):813-820. PubMed ID: 27671308
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Huang Y; Lichtenberger LM; Taylor M; Bottsford-Miller JN; Haemmerle M; Wagner MJ; Lyons Y; Pradeep S; Hu W; Previs RA; Hansen JM; Fang D; Dorniak PL; Filant J; Dial EJ; Shen F; Hatakeyama H; Sood AK
Mol Cancer Ther; 2016 Dec; 15(12):2894-2904. PubMed ID: 27638860
[TBL] [Abstract][Full Text] [Related]
15. Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.
Meier R; Braren R; Kosanke Y; Bussemer J; Neff F; Wildgruber M; Schwarzenböck S; Frank A; Haller B; Hohlbaum AM; Schwaiger M; Gille H; Rummeny EJ; Beer AJ
PLoS One; 2014; 9(5):e94972. PubMed ID: 24801709
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells.
Mouratidis PXE; Ter Haar G
Int J Hyperthermia; 2021; 38(1):1443-1456. PubMed ID: 34612127
[TBL] [Abstract][Full Text] [Related]
17. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.
Davies S; Dai D; Pickett G; Thiel KW; Korovkina VP; Leslie KK
Oncol Rep; 2011 Mar; 25(3):855-62. PubMed ID: 21240464
[TBL] [Abstract][Full Text] [Related]
18. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
Stone RL; Sood AK; Coleman RL
Lancet Oncol; 2010 May; 11(5):465-75. PubMed ID: 20226736
[TBL] [Abstract][Full Text] [Related]
19. Direct antitumor activity of bevacizumab: an overlooked mechanism?
Wang Z; Li J; Guo J; Wei P
Front Pharmacol; 2024; 15():1394878. PubMed ID: 38716237
[No Abstract] [Full Text] [Related]
20. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
